Who makes PF-04937319 split-dose?

PF-04937319 split-dose is developed by Pfizer.

What development phase is PF-04937319 split-dose in?

PF-04937319 split-dose is in Phase 1.

Last reviewed 2026-04-19 · How we verify

PF-04937319 split-dose

Pfizer · Phase 1 active Small molecule

At a glance

Generic name	PF-04937319 split-dose
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes (PHASE1)
A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-04937319 split-dose CI brief — competitive landscape report
PF-04937319 split-dose updates RSS · CI watch RSS
Pfizer portfolio CI